The Hindu·3 min read·medium
Cohance Lifesciences reports ₹45.19 crore loss in Q1 on lower revenue
T
The Hindu Bureau
✦AI Summary
Cohance Lifesciences reported a net loss of ₹45.19 crore for the first quarter, citing lower revenue and shipment phasing in its CDMO business. The company also disclosed receiving five observations from the U.S. FDA following an inspection of its Hyderabad facility.
Contract development and manufacturing organisation (CDMO) Cohance Lifesciences (formerly Suven Pharmaceuticals) reported ₹45.19 crore loss on a consolidated basis for the quarter ended June compared to the ₹46.40 crore net profit in the year earlier period.
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in